| Ytd | -24.84% | |
| 1y | -66.11% |
| Open | 1.15 | Prev Close | 1.14 | Low | 1.15 | High | 1.25 | Mkt Cap | 324.59M |
| Vol | 6.04M | Avg Vol | 4.72M | EPS | -0.08 | P/E | N/A | Forward P/E | -7.15 |
| Beta | 0.73 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.13 | 200-d Avg | 1.63 | 1yr Est | 5.50 |
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) wit
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better th
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the